CL2017003323A1 - Composición para el tratamiento de nafld - Google Patents

Composición para el tratamiento de nafld

Info

Publication number
CL2017003323A1
CL2017003323A1 CL2017003323A CL2017003323A CL2017003323A1 CL 2017003323 A1 CL2017003323 A1 CL 2017003323A1 CL 2017003323 A CL2017003323 A CL 2017003323A CL 2017003323 A CL2017003323 A CL 2017003323A CL 2017003323 A1 CL2017003323 A1 CL 2017003323A1
Authority
CL
Chile
Prior art keywords
nafld
pufa
composition
treatment
pcb
Prior art date
Application number
CL2017003323A
Other languages
English (en)
Inventor
Carola Rosseland
Original Assignee
Pronova Biopharma Norge As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pronova Biopharma Norge As filed Critical Pronova Biopharma Norge As
Publication of CL2017003323A1 publication Critical patent/CL2017003323A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A61K31/232—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having three or more double bonds, e.g. etretinate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Nutrition Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Emergency Medicine (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

<p>COMPOSICIÓN Y MÉTODO PARA TRATAR PACIENTES DIAGNOSTICADOS CON NAFLD. LA COMPOSICIÓN CONTIENE ÁCIDOS GRASOS POLIINSATURADOS N–3 (PUFA) PARA EL TRATAMIENTO DE PACIENTES CON NAFLD, DONDE SE HA MINIMIZADO LA CANTIDAD DE PCB 153. LA COMPOSICIÓN SE ADMINISTRA A UN PACIENTE EN UNA CANTIDAD Y TIEMPO SUFICIENTES PARA AUMENTAR EL NIVEL DE N–3 PUFA O PARA CORREGIR UNA DEFICIENCIA DE LOS N–3 PUFA EN LA SANGRE DEL PACIENTE. EL MÉTODO AUMENTA EL NIVEL DE N–3 PUFA SIN CONTRIBUIR A LA CARGA CORPORAL DE PCB 153</p>
CL2017003323A 2015-06-26 2017-12-21 Composición para el tratamiento de nafld CL2017003323A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
NO20150838 2015-06-26

Publications (1)

Publication Number Publication Date
CL2017003323A1 true CL2017003323A1 (es) 2018-05-11

Family

ID=56896729

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2017003323A CL2017003323A1 (es) 2015-06-26 2017-12-21 Composición para el tratamiento de nafld

Country Status (10)

Country Link
US (2) US20160374975A1 (es)
EP (1) EP3313391A1 (es)
JP (2) JP2018522868A (es)
CN (1) CN108024984A (es)
AU (1) AU2016281819B2 (es)
BR (1) BR112017027909A2 (es)
CA (1) CA2990140A1 (es)
CL (1) CL2017003323A1 (es)
MX (1) MX2017017136A (es)
WO (1) WO2016207734A1 (es)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021028737A1 (es) * 2019-08-13 2021-02-18 Team Foods Colombia S.A. Composición lipídica que comprende antioxidantes y polifenoles naturales como alternativa no farmacológica para el tratamiento y la prevención de nafld

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2019009337A (es) * 2017-02-07 2019-09-19 Fresenius Kabi Deutschland Gmbh Eficacia a largo plazo de tratamiento de enfermedad hepatica con epa y dha.
CN108095085A (zh) * 2017-12-25 2018-06-01 陕西三正医用营养有限公司 一种糖尿病特定全营养特殊医学用途配方食品及其制备方法
CN108354919A (zh) * 2017-12-29 2018-08-03 广东海洋大学 一种用于提高抗氧化功能的不饱和脂肪酸组合物及其应用
GB202209414D0 (en) * 2022-06-27 2022-08-10 Aker Biomarine Antarctic As Uses for phospholipid compositions

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0202188D0 (sv) 2002-07-11 2002-07-11 Pronova Biocare As A process for decreasing environmental pollutants in an oil or a fat, a volatile fat or oil environmental pollutants decreasing working fluid, a health supplement, and an animal feed product
WO2006017627A2 (en) * 2004-08-06 2006-02-16 Barry Sears Dietary compositions comprising docosahexaenoic acid and eicosapentaenoic acid and use thereof for treating insulin resistance
WO2007081773A2 (en) * 2006-01-05 2007-07-19 Reliant Pharmaceuticals, Inc Treatment of fatty liver
US20110166228A1 (en) * 2006-11-01 2011-07-07 Anne Kristin Holmeide Composition
CA2685272A1 (en) * 2007-04-26 2008-11-06 Patrick Adlercreutz A polyunsaturated fatty acid (pufa) enriched marine oil comprising eicosapentaenoic acid (epa) and docosahexaenoic acid (dha), and a process of production thereof
CL2009001343A1 (es) 2009-06-02 2009-07-10 Golden Omega S A Proceso de obtencion concentrado de esteres de epa y dha a partir de aceite marino, que comprende agregar al aceite alcali y agua a menos de 100 grados celsius, agregar solvente, separar fase de refinado, agregar acido, separar la fase no acuosa y agregar alcohol y un catalizador a menos de 150 grados celsius, desolventilizar y destilar.
PE20130491A1 (es) * 2009-12-30 2013-05-02 Basf Pharma Callanish Ltd Proceso simulado de separacion cromatografica de lecho movil para la purificacion de acidos grasos poliinsaturados
US9145533B2 (en) 2010-09-24 2015-09-29 Pronova Blopharm Norge AS Process for concentrating omega-3 fatty acids
WO2012160442A1 (en) * 2011-05-20 2012-11-29 Pharma Marine As Method to simultaneously enhance omega-3 and remove volatile contaminants
US8258330B1 (en) 2012-01-04 2012-09-04 Naturalis, S.A. Carrier fluid composition comprising fatty acids ethyl esters and process for reducing the concentration of persistent organic pollutants in fish oil
CA2890216C (en) * 2012-11-02 2021-04-13 Pronova Biopharma Norge As Removal of undesired components from oil compositions
US9889108B2 (en) 2013-03-15 2018-02-13 Mochida Pharmaceutical Co., Ltd. Compositions and methods for treating non-alcoholic steatohepatitis
WO2015053379A1 (en) * 2013-10-07 2015-04-16 Mochida Pharmaceutical Co., Ltd. Compositions and methods for treating non-alcoholic steatohepatitis
KR102258677B1 (ko) * 2013-12-10 2021-06-01 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 간 질환의 감별 진단
CN103989666A (zh) * 2014-04-11 2014-08-20 浙江海洋学院 n-3多不饱和脂肪酸在治疗非酒精性脂肪肝病药物中的应用
CN107666904B (zh) * 2015-03-26 2022-02-01 提贝托·布鲁泽塞 多不饱和脂肪酸的纯化组合物、其制备方法及其用途

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021028737A1 (es) * 2019-08-13 2021-02-18 Team Foods Colombia S.A. Composición lipídica que comprende antioxidantes y polifenoles naturales como alternativa no farmacológica para el tratamiento y la prevención de nafld
GB2593317A (en) * 2019-08-13 2021-09-22 Team Foods Colombia Sa Lipid composition comprising antioxidants and natural polyphenols as a non-pharmacological alternative for the treatment and prevention of NAFLD

Also Published As

Publication number Publication date
US20160374975A1 (en) 2016-12-29
BR112017027909A2 (pt) 2018-08-28
US20160374977A1 (en) 2016-12-29
CN108024984A (zh) 2018-05-11
AU2016281819B2 (en) 2021-10-14
EP3313391A1 (en) 2018-05-02
CA2990140A1 (en) 2016-12-29
AU2016281819A1 (en) 2018-02-01
WO2016207734A1 (en) 2016-12-29
MX2017017136A (es) 2018-05-28
JP2018522868A (ja) 2018-08-16
JP2020121972A (ja) 2020-08-13

Similar Documents

Publication Publication Date Title
CL2017003323A1 (es) Composición para el tratamiento de nafld
CL2017003006A1 (es) Métodos de acondicionamiento de pacientes para tratamiento con linfocitos t
CL2017003005A1 (es) Métodos de diagnóstico para tratamiento con linfocitos t
BR112017005790A2 (pt) dispositivos de reparo vascular e métodos de uso
MX2019007586A (es) Composiciones que comprenden tacrolimus para el tratamiento de enfermedades inflamatorias intraoculares.
WO2017163132A3 (en) Use of umbilical cord blood derived exosomes for tissue repair
CL2012002037A1 (es) Uso de agonista doble del glucagon-glp-1 como agente inotropico en el tratamiento de la cardiopatía o la disfuncion cardiaca
CL2017002825A1 (es) Formulaciones de tpp1 y métodos para tratar la enfermedad de cln2
MY185691A (en) An asseointegrable device
MX2018002546A (es) Composiciones que comprenden un compuesto de urolitina.
CR20170320A (es) Mezcla de ácidos carboxílicos para tratar pacientes con insuficiencia renal
CY1122615T1 (el) Θεραπεια με βλαστοκυτταρα σε παθολογιες τουενδομητριου
MX2020007462A (es) Metodos de tratamiento de enfermedades inflamatorias cronicas.
EA201891610A1 (ru) Производные 3-(карбоксиэтил)-8-амино-2-оксо-1,3-диазаспиро[4.5]декана
PE20200794A1 (es) Composicion para su uso en la prevencion y el tratamiento de patologias del aparato cardiovascular
CO2018000768A2 (es) Administración intravenosa de citrulina durante la cirugía
BR112016028561A2 (pt) composição, forma de dosagem, e, métodos para reduzir o risco para mortalidade em um indivíduo, o risco para uma doença ou condição em um indivíduo, triglicerídeos em um sangue de indivíduo, a frequência cardíaca em repouso de um indivíduo, o colesterol de lipoproteína de densidade não alta em um indivíduo, o colesterol total em um indivíduo, a apolipoproteína b em um sangue de indivíduo, pressão sanguínea sistólica em um indivíduo e a pressão sanguínea diastólica em um indivíduo, para prolongar a vida de um indivíduo, para tratar hipertrigliceridemia em um indivíduo e para aumentar um índice de ômega-3 em células vermelhas do sangue de um indivíduo.
MX2021011799A (es) Antagonistas de semaforina 4d para usarlos en la terapia contra el cancer.
AR104194A1 (es) Composición del factor de von willebrand
MX2018005566A (es) Dispositivo y metodo para el tratamiento de un implante oseo artificial con sangre.
IL272443A (en) Glycyrrhetinic acid derivatives for treating hyperkalemia
EA201790537A1 (ru) Дипептидилкетоамидные соединения и их применение для лечения и/или предотвращения накопления жира
EA201792609A1 (ru) Протез связки
BR112016030291A2 (pt) terapia de combinação
EA202090728A1 (ru) Применение нор-урсодезоксихолевой кислоты для снижения печеночного жира